路透7月27日 - 根据周一发布的简报文件，美国食品和药物管理局（FDA）的评审人员对Capricor Therapeutics公司旗下 CAPR.O 细胞疗法“德拉米奥塞尔”（deramiocel）是否具备足够证据证明其对杜氏肌营养不良症伴发心肌病的治疗有效性表示了担忧。
路透7月27日 - 根据周一发布的简报文件，美国食品和药物管理局（FDA）的评审人员对Capricor Therapeutics公司旗下 CAPR.O 细胞疗法“德拉米奥塞尔”（deramiocel）是否具备足够证据证明其对杜氏肌营养不良症伴发心肌病的治疗有效性表示了担忧。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.